Ad
related to: lupus treatment guidelines 2022 ada criteria 2020 chart
Search results
Results from the WOW.Com Content Network
Anifrolumab, sold under the brand name Saphnelo, is a monoclonal antibody used for the treatment of systemic lupus erythematosus. [5] [7] It binds to the type I interferon receptor, blocking the activity of type I interferons such as interferon-α and interferon-β.
In 1999 a study noted, "In recent years there has been growing concern regarding the diagnosis of incomplete forms of the autoimmune diseases" [26] and the first classification criteria were proposed in that year. [1] Historically the condition was sometimes called undifferentiated connective tissue syndrome, latent lupus or incomplete lupus. [1]
Lupus erythematosus is a collection of autoimmune diseases in which the human immune system becomes hyperactive and attacks healthy tissues. [1] Symptoms of these diseases can affect many different body systems, including joints , skin , kidneys , blood cells , heart , and lungs .
Discoid lupus erythematosus is the most common type of chronic cutaneous lupus (CCLE), an autoimmune skin condition on the lupus erythematosus spectrum of illnesses. [ 1 ] [ 2 ] It presents with red, painful, inflamed and coin-shaped patches of skin with a scaly and crusty appearance, most often on the scalp, cheeks, and ears.
Furthermore, anti-histone antibodies can also be positive in drug-induced lupus. [citation needed] Anti-Histone antibodies are positive in up to 95% of patients with drug induced lupus. The most common medications associated with drug induced lupus are hydralazine, procainamide, isoniazid, methyldopa, chlorpromazine, quinidine, and minocycline. [9]
Lupus, formally called systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] Symptoms vary among people and may be mild to severe. [ 1 ]
Tumid lupus erythematosus is a rare, but distinctive entity in which patients present with edematous erythematous plaque. [ 2 ] Lupus erythematosus tumidus (LET) was reported by Henri Gougerot and Burnier R. in 1930.
Treatment for a lupus anticoagulant is usually undertaken in the context of documented thrombosis, such as extremity phlebitis or dural sinus vein thrombosis. Patients with a well-documented (i.e., present at least twice) lupus anticoagulant and a history of thrombosis should be considered candidates for indefinite treatment with anticoagulants.
Ad
related to: lupus treatment guidelines 2022 ada criteria 2020 chart